Zymonostics is a spin-out company set up to develop and commercialize a new class of diagnostic test based on the highly potent biomarker – Type topoisomerase I (TopI) - which the company now seeks to validate for TB diagnosis. Built on a strong IP portfolio and an established technology platform, TOPO-TB is a rapid, biomarker-based and low-cost system for mycobacteria detection, with unrivalled user-friendliness and portability. TOPO-TB allows rapid Mtb diagnosis in sputum and non-sputum samples using a cost efficient and easily operated platform. This solution has the potential to be the first diagnostic test capable of detecting TB mycobacteria in a non-sputum sample, holding obvious advantages for diagnostic procedure outcomes and ultimately public health quality.
Innovayt assisted Zymonostics with the writing and development of the proposal that was approved for funding by the Horizon 2020 SME instrument.
For more information contact Patricia Sousa